Stockholm, Sweden – Barnik Invest Group today announced the acquisition of Sanikma AB and the rebranding of the company to StartUpPharma Int. AB. This strategic move strengthens StartUpPharmas position in the life sciences industry with its market access capabilities in the food supplement, pharmaceutical, biotech, and medical device sectors.
StartUpPharma Int. AB is dedicated to providing comprehensive solutions to clients seeking to establish and grow their businesses in international markets. The company offers a range of services including: product development and market entry strategies, regulatory and compliance support, distribution and sales network development, marketing and branding services.
“The acquisition of Sanikma AB and the rebranding as StartUpPharma Int. AB align with our vision to drive innovation and growth in the life sciences industry and strengthening our position as a unique 360° solution in life science,” said Hamid Bakhshi, CEO of Barnik Invest Group. “We are excited to leverage the expertise and resources in StartUpPharma to create a powerful platform that will enable our clients to achieve their business goals.”
With a strong team of experienced professionals and a global network of partners, StartUpPharma Int. AB is well-positioned to provide exceptional value to its clients.
For more information, please contact;
Hamid Bakhshi, CEO
Telephone: +46738531165
E-mail: hamid.bakhshi@barnikinvest.com
About Barnik Invest Group
Barnik Invest Group is a leading 360 solution partner for small Life Science companies in the Nordics. The company provides a comprehensive suite of services to support its portfolio companies, including capital, clinical development, expertise, and commercialization. Through its fully-owned subsidiaries, Medicorent and StartUpPharma, Barnik Invest offers CRO services, outsourcing, recruitment, distribution, product development and commercialization solutions. Barnik’s mission is to nurture promising life science companies from early clinical development phase to commercialization, enabling them to achieve positive cash flows or successful exits and ultimately enhancing patient well-being and improving human health worldwide. For more information visit www.barnikinvest.com.
